Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 970

1.

Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.

van der Flier FE, Kwee CMB, Cath DC, Batelaan NM, Groenink L, Duits P, van der Veen DC, van Balkom AJLM, Baas JMP.

BMC Psychiatry. 2019 Feb 13;19(1):69. doi: 10.1186/s12888-019-2022-x.

2.

Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder.

Pretzsch CM, Freyberg J, Voinescu B, Lythgoe D, Horder J, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, Edden RAE, Williams S, Murphy DGM, Daly E, McAlonan GM.

Neuropsychopharmacology. 2019 Feb 6. doi: 10.1038/s41386-019-0333-8. [Epub ahead of print]

PMID:
30758329
3.

Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.

Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C.

Epilepsia. 2019 Feb 11. doi: 10.1111/epi.14670. [Epub ahead of print]

PMID:
30740695
4.

Cannabidiol Increases Proliferation, Migration, Tubulogenesis, and Integrity of Human Brain Endothelial Cells through TRPV2 Activation.

Luo H, Rossi E, Saubamea B, Chasseigneaux S, Cochois V, Choublier N, Smirnova M, Glacial F, Perrière N, Bourdoulous S, Smadja DM, Menet MC, Couraud PO, Cisternino S, Declèves X.

Mol Pharm. 2019 Feb 5. doi: 10.1021/acs.molpharmaceut.8b01252. [Epub ahead of print]

PMID:
30721081
5.

Abnormal cannabidiol modulates vitamin A metabolism by acting as a competitive inhibitor of CRBP1.

Silvaroli JA, Widjaja-Adhi MAK, Trischman T, Chelstowska S, Horwitz S, Banerjee S, Kiser PD, Blaner WS, Golczak M.

ACS Chem Biol. 2019 Feb 5. doi: 10.1021/acschembio.8b01070. [Epub ahead of print]

PMID:
30721022
6.

Case Report: Clinical Outcome and Image Response of Two Patients With Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol.

Dall'Stella PB, Docema MFL, Maldaun MVC, Feher O, Lancellotti CLP.

Front Oncol. 2019 Jan 18;8:643. doi: 10.3389/fonc.2018.00643. eCollection 2018.

7.

Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells.

Alharris E, Singh NP, Nagarkatti PS, Nagarkatti M.

Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.

8.

Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG.

Eur Arch Psychiatry Clin Neurosci. 2019 Jan 31. doi: 10.1007/s00406-019-00982-6. [Epub ahead of print] Review.

PMID:
30706171
9.

Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review.

Turna J, Syan SK, Frey BN, Rush B, Costello J, Weiss M, MacKillop J.

Alcohol Clin Exp Res. 2019 Jan 30. doi: 10.1111/acer.13964. [Epub ahead of print]

PMID:
30698831
10.

Decarbonylation: a metabolic pathway of cannabidiol in humans.

Kraemer M, Broecker S, Madea B, Hess C.

Drug Test Anal. 2019 Jan 30. doi: 10.1002/dta.2572. [Epub ahead of print]

PMID:
30698361
11.

Cannabidiol May Help Normalize Brain Function in Psychosis.

Slomski A.

JAMA. 2019 Jan 29;321(4):335. doi: 10.1001/jama.2018.22032. No abstract available.

PMID:
30694318
12.

US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions.

Kogan L, Schoenfeld-Tacher R, Hellyer P, Rishniw M.

Front Vet Sci. 2019 Jan 10;5:338. doi: 10.3389/fvets.2018.00338. eCollection 2018.

13.

Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities.

Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, Koren G, Berkovitch M.

Front Pharmacol. 2019 Jan 9;9:1521. doi: 10.3389/fphar.2018.01521. eCollection 2018.

14.

Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of Tuberous Sclerosis Complex.

Serra I, Scheldeman C, Bazelot M, Whalley BJ, Dallas ML, de Witte PAM, Williams CM.

Behav Brain Res. 2019 Jan 23;363:135-144. doi: 10.1016/j.bbr.2019.01.040. [Epub ahead of print]

PMID:
30684511
15.

Cannabidiol (Epidiolex) for epilepsy.

[No authors listed]

Med Lett Drugs Ther. 2018 Nov 5;60(1559):182-184. No abstract available.

PMID:
30681657
16.

A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.

Solowij N, Broyd S, Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R.

Eur Arch Psychiatry Clin Neurosci. 2019 Jan 19. doi: 10.1007/s00406-019-00978-2. [Epub ahead of print]

PMID:
30661105
17.

Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells.

Jeong S, Yun HK, Jeong YA, Jo MJ, Kang SH, Kim JL, Kim DY, Park SH, Kim BR, Na YJ, Lee SI, Kim HD, Kim DH, Oh SC, Lee DH.

Cancer Lett. 2019 Jan 18;447:12-23. doi: 10.1016/j.canlet.2019.01.011. [Epub ahead of print]

PMID:
30660647
18.

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.

Patti F.

Neurodegener Dis Manag. 2019 Apr;9(2s):3-7. doi: 10.2217/nmt-2018-0049. Epub 2019 Jan 18.

PMID:
30657027
19.

Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.

Marková J.

Neurodegener Dis Manag. 2019 Apr;9(2s):9-13. doi: 10.2217/nmt-2018-0050. Epub 2019 Jan 18.

PMID:
30657024
20.

Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.

Ziemssen T.

Neurodegener Dis Manag. 2019 Apr;9(2s):1-2. doi: 10.2217/nmt-2018-0048. Epub 2019 Jan 18.

PMID:
30657019

Supplemental Content

Loading ...
Support Center